Chiesi Group’s idebenone faced a regulatory setback last month after the U.S. FDA issued a complete response letter (CRL) to the company’s NDA for Leber hereditary optic neuropathy (LHON), a rare inherited disorder that causes sudden vision loss.But a chance missed for Chiesi may be an opportunity for gene therapies, including Gensight Biologics SA’s lenadogene nolparvovec (Lumevoq; GS-010).
Chiesi Farmaceutici SpA has identified new D-3-phosphoglycerate dehydrogenase (3-PGDH; PHGDH) inhibitors for the treatment of idiopathic pulmonary fibrosis.
Chiesi Farmaceutici SpA has divulged sodium channel protein type 9 subunit α (Nav1.7) channel blockers reported to be useful for the treatment of chronic cough.
Researchers from Chiesi Farmaceutici SpA published new clinical data for CHF-6467, a recombinant modified form of human nerve growth factor (NGF), being evaluated for the treatment of neonatal hypoxic-ischemic encephalopathy (HIE).
Chiesi Farmaceutici SpA has divulged TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis.
A woman who allegedly made nearly $300,000 last year on insider trading based on undisclosed information about a pending biopharma acquisition will have to disgorge her profits, along with interest, to the U.S. Treasury, but she will face no other penalties.
Chiesi Farmaceutici SpA presented data for novel lung-targeted muscarinic M3 receptor antagonists/β2-adrenoceptor agonists (MABAs) as candidates for the treatment of chronic obstructive pulmonary disease (COPD).
Chiesi Farmaceutici SpA has synthesized heterocyclic derivatives acting as Janus kinase (JAK) inhibitors reported to be useful for the treatment of acute lung injury, asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.
Chiesi Farmaceutici SpA has detailed new discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Chiesi Farmaceutici SpA has prepared azetidine derivatives acting as cathepsin C (dipeptidyl peptidase 1, DPP-1) inhibitors and reported to be useful for the treatment of non-cystic fibrosis bronchiectasis (NCFBE), among others.
